Skip to main content
Green Templeton College

Professor Sir Martin Landray

Professor of Medicine and Epidemiology, Nuffield Department of Population Health

Professor Sir Martin Landray has over 25 years' experience of leading innovative clinical trials for common and life-threatening disorders. He makes extensive use of data and technology and plays a major role in clinical research policy (e.g. with WHO, MHRA, FDA and government).

Head and shoulders image of Professor Sir Martin Landray for Find an Expert

About

Sir Martin Landray is Professor of Medicine and Epidemiology in the Nuffield Department of Population Health. Since March 2020, he has co-led the RECOVERY trial and is also Chief Executive Officer of Protas, a not-for-profit organisation focused on smarter randomised trials for better public health.

Professor Landray’s work seeks to further understanding of the determinants of common diseases chiefly through the design, conduct and analysis of efficient, large-scale clinical trials. He has led a series of major clinical trials, chiefly of treatments for cardiovascular and kidney disease.

He continues to practise clinical medicine as an Honorary Consultant Physician in the Department of Cardiology at Oxford University Hospitals NHS Foundation Trust. In 2021, he was elected Fellow of the Academy of Medical Sciences and was knighted for services to public health and science.

Expertise

  • Clinical trials
  • Research policy
  • Health data and technology

Selected publications

Clinical trials methods and policy:

Collins R, Bowman L, Landray M, Peto R. The Magic of Randomization versus the Myth of Real-World Evidence. N Engl J Med 2020; 382:674-678

RECOVERY (COVID-19):

RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:665-676

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:1637-1645

RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020;384:693-704

RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383:2030-2040

Cardiovascular trials:

HPS3/TIMI55-REVEAL Collaborative Group. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New Engl J Med 2017;377:1217-27

HPS2-THRIVE Collaborative Group. Effects of Extended-release niacin and laropiprant in high-risk individuals. New Engl J Med 2014;371:203-212

Kidney disease trials:

EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New Engl J Med 2022;388:117-127

SHARP Collaborative Group. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92

UK Biobank:

Sudlow C et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Medicine 2015;3:e1001779

Media experience

Professor Landray has experience in working with the media, including television, radio and print.

Languages

English